Cogent Biosciences, Inc. Cogent Biosciences, Inc.

Cogent Biosciences, Inc.

COGT

Kedudukan dalam Saham #3284
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted... Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
Harga Saham
$31.20
Modal Pasaran
$5.41B
Perubahan (1 hari)
3.97%
Perubahan (1 tahun)
92.36%
Negara
US
Perdagangan Cogent Biosciences, Inc. (COGT)

Kategori

Healthcare
Bilangan saham terbitan bagi Cogent Biosciences, Inc. (COGT)
Bilangan saham terbitan setakat June 2026: 171.01M
Menurut laporan kewangan terkini dan harga saham Cogent Biosciences, Inc., bilangan saham terbitan semasa ialah 171.01M. Pada akhir December 2023, syarikat mempunyai 79.66M saham terbitan. Bilangan saham terbitan biasanya dipengaruhi oleh pecahan saham dan pembelian balik saham.
Sejarah saham terbitan untuk Cogent Biosciences, Inc. (COGT) dari 2015 hingga 2026
Saham terbitan pada akhir setiap tahun
Tahun Saham Terbitan Ubah
2026 (TTM) 171.01M 64.66%
2024 103.86M 30.38%
2023 79.66M 35.61%
2022 58.74M 51.66%
2021 38.73M 249.52%
2020 11.08M 45.42%
2019 7.62M 22.43%
2018 6.22M -15.85%
2017 7.40M 26.32%
2016 5.86M 0.00%
2015 5.86M 0.00%
Saham terbitan bagi syarikat atau pesaing yang serupa
Syarikat Saham Terbitan Perbezaan Negara
253.90M 48.47%
US
396.00M 131.57%
US
478.91M 180.06%
AU
- -
CH
62.19M -63.64%
NL